Status:

COMPLETED

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

Lead Sponsor:

Axsome Therapeutics, Inc.

Conditions:

Agitation in Patients With Dementia of the Alzheimer's Type

Alzheimer Disease

Eligibility:

All Genders

65-90 years

Phase:

PHASE3

Brief Summary

This is a multi-center, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of AXS-05 compared to placebo in the treatment of agitation symptoms in subjec...

Detailed Description

Enrolled patients will first enter a 9-week, open-label stabilization period, during which they will be treated with AXS-05 and monitored for a treatment response. Patients who experience a treatment ...

Eligibility Criteria

Inclusion

  • Diagnosis of probable Alzheimer's disease (AD) based on the 2011 National Institute on Aging-Alzheimer Association (NIA-AA) criteria.
  • Diagnosis of clinically signification agitation resulting from probable AD according to the International Psychogeriatric Association (IPA) provisional definition of agitation.

Exclusion

  • Patient has dementia predominantly of non-Alzheimer's type.
  • Patient has symptoms of agitation that are not secondary to AD (e.g., pain, other psychiatric disorder or delirium due to a metabolic disorder, systemic infection, or substance-induced).
  • Unable to comply with study procedures.
  • Medically inappropriate for study participation in the opinion of the investigator.

Key Trial Info

Start Date :

December 31 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 21 2022

Estimated Enrollment :

178 Patients enrolled

Trial Details

Trial ID

NCT04797715

Start Date

December 31 2020

End Date

November 21 2022

Last Update

November 29 2023

Active Locations (63)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 16 (63 locations)

1

Clinical Research Site

Sun City, Arizona, United States, 85351

2

Clinical Research Site

Tucson, Arizona, United States, 85710

3

Clinical Research Site

Chula Vista, California, United States, 91910

4

Clinical Research Site

Imperial, California, United States, 92251